Ferric pyrophosphate
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Ferric pyrophosphate
- Structure (SMILES)
- O(P(=O)([O-])[O-])P([O-])(=O)[O-].[Fe+3].O(P(=O)([O-])[O-])P([O-])(=O)[O-].O(P(=O)([O-])[O-])P([O-])(=O)[O-].[Fe+3].[Fe+3].[Fe+3]
- diphosphoric acid iron 3 salt 3 4
- DIPHOSPHORIC ACID IRON(3+) SALT (3:4)
- ferric pyrophosphate
- Ferric pyrophosphate
- FERRIC PYROPHOSPHATE [FCC]
- FERRIC PYROPHOSPHATE [HSDB]
- FERRIC PYROPHOSPHATE [MART.]
- FERRIC PYROPHOSPHATE [MI]
- FERRIC PYROPHOSPHATE [VANDF]
- Ferric pyrophosphate [WHO-DD]
- ferric pyrophosphate fcc
- ferric pyrophosphate hsdb
- ferric pyrophosphate mart
- ferric pyrophosphate mi
- ferric pyrophosphate vandf
- ferric pyrophosphate who dd
- Iron (as pyrophosphate)
- iron as pyrophosphate
- iron iii pyrophosphate
- Iron(iii) pyrophosphate
- CAS registry numbers
- 10058-44-3
- ChEMBL ID
- CHEMBL4297752
- InChIKey
- CADNYOZXMIKYPR-UHFFFAOYSA-B
- PubChem compound IDs
- 24877
- RxNorm IDs (RxCUI)
- 1607976
- FDA ingredient codes (UNII)
- QK8899250F
- First in class
- No
- Orphan designation
- No
- Condition
- Anemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004272
- Subject identifier
- D000740
- Condition
- Helicobacter Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000961
- Subject identifier
- D016481
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000961
- Highest recorded phase
- 1
- Condition identifier
- HP_0001891
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002280
- Highest recorded phase
- 3
Reported adverse events
- Event
- medical device site joint inflammation
- Reports
- 1
- Reporting signal score
- 12.0835
- NCT00867867
- NCT05957328
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Heavy atoms
- 31
- Monoisotopic mass
- 745.47552
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 0
Related records
Trials (121)
- .Patient Blood Management Program in Liver Transplantation
- 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
- A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM
- A Before and After Study Studying the Impact of an Analgesia Protocol After Discharge From Outpatient Surgery
- A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 3 Study in Participants With Moderate to Severe Psoriasis
- A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
- A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.
- A Randomized Trial of Oral Iron Therapy in Fibromyalgia
- A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
- A Study of Idazoxan in Healthy Participants
- A Study to Compare Liposomal Iron With Ferrous Ascorbate in the Treatment of Iron Deficiency Anemia in Children
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants
- A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
- A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
- A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD
In development for (2)
- Anemia Phase 3
- Helicobacter pylori infectious disease Phase 1